We have developed a proprietary iNKT cell expansion platform that allows us to manufacture at least 100 doses of CAR-modified iNKT cells from single donor leukopak in a cost-effective manner. The expanded CAR-modified iNKT cells are > 95% of CD3+iTCR+ and kill cancer cells specifically.